Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Bellecapital International Ltd.

Key Points

• Bellecapital International Ltd. increased its holdings in Regeneron Pharmaceuticals by 32.7% during the second quarter, acquiring an additional 6,283 shares for a total ownership of 25,503 shares valued at $13.39 million.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the last quarter, significantly exceeding expectations of $8.43, with revenues of $3.68 billion, a 3.6% increase year-over-year.
• Several analysts have updated their price targets for Regeneron, with Citigroup setting a new target of $660 and Guggenheim raising theirs to $815, reflecting a consensus rating of "Moderate Buy".

Bellecapital International Ltd. boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 32.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,503 shares of the biopharmaceutical company's stock after purchasing an additional 6,283 shares during the period. Regeneron Pharmaceuticals makes up 2.4% of Bellecapital International Ltd.'s portfolio, making the stock its 16th biggest position. Bellecapital International Ltd.'s holdings in Regeneron Pharmaceuticals were worth $13,389,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after buying an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Regeneron Pharmaceuticals by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after buying an additional 89,579 shares during the last quarter. Amundi increased its stake in shares of Regeneron Pharmaceuticals by 3.4% in the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company's stock worth $979,794,000 after buying an additional 52,166 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after buying an additional 174,056 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2.1% in the first quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company's stock worth $458,211,000 after buying an additional 14,921 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $576.42 on Thursday. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,020.55. The firm has a market capitalization of $61.09 billion, a PE ratio of 14.53, a P/E/G ratio of 1.84 and a beta of 0.31. The firm has a 50-day moving average of $574.15 and a two-hundred day moving average of $563.61.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period in the prior year, the firm earned $11.56 earnings per share. The firm's revenue was up 3.6% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a "buy" rating in a research note on Monday. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a research note on Friday, August 1st. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a report on Monday, August 4th. Finally, Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $817.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.